PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27089846-4	2016	The results demonstrated that both tolcapone and entacapone exhibited inhibitory effects on UGT1A1, UGT1A7, UGT1A9 and UGT1A10.	Tolcapone	35-44	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	92-98	
27089846-5	2016	In contrast to entacapone, tolcapone exhibited more potent inhibitory effects on UGT1A1, UGT1A7, and UGT1A10, while their inhibitory potentials against UGT1A9 were comparable.	Tolcapone	27-36	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	81-87	
27089846-6	2016	It is noteworthy that the inhibition constants (Ki) of tolcapone and entacapone against bilirubin-O-glucuronidation in human liver microsomes (HLM) are determined as 0.68muM and 30.82muM, respectively, which means that the inhibition potency of tolcapone on UGT1A1 mediated bilirubin-O-glucuronidation in HLM is much higher than that of entacapone.	Tolcapone	55-64	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	258-264	
27089846-7	2016	Furthermore, the potential risks of tolcapone or entacapone via inhibition of human UGT1A1 were quantitatively predicted by the ratio of the areas under the plasma drug concentration-time curve (AUC).	Tolcapone	36-45	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	84-90	
27089846-8	2016	The results indicate that tolcapone may result in significant increase in AUC of bilirubin or the drugs primarily metabolized by UGT1A1, while entacapone is unlikely to cause a significant DDI through inhibition of UGT1A1.	Tolcapone	26-35	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	129-135